Cart
sales@molnova.com
GW 441756
CAS No. 504433-23-2
GW 441756( GW-441756 | GW 441756 | GW441756 )
Catalog No. M17527 CAS No. 504433-23-2
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 46 | In Stock |
|
| 10MG | 72 | In Stock |
|
| 25MG | 140 | In Stock |
|
| 50MG | 213 | In Stock |
|
| 100MG | 323 | In Stock |
|
| 500MG | 764 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGW 441756
-
NoteResearch use only, not for human use.
-
Brief DescriptionGW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
-
DescriptionGW-441756 is a potent inhibitor of TrkA (IC50 = 2 nM). Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma.
-
In VitroImmunofluorescence Cell Line:Spinal cord neurons cells Concentration:1 μM Incubation Time:48 hours Result:Abolished BmK NSPK-induced neurite outgrowth.
-
In Vivo——
-
SynonymsGW-441756 | GW 441756 | GW441756
-
PathwayEndocrinology/Hormones
-
TargetAChR
-
RecptorCDK2| C-Raf-1| TrkA
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number504433-23-2
-
Formula Weight275.3
-
Molecular FormulaC17H13N3O
-
Purity>98% (HPLC)
-
SolubilityDMSO : 17.5 mg/mL. 63.57 mM; H2O : < 0.1 mg/mL
-
SMILESCn1cc(c2ccccc12)C=C1c2c(cccn2)NC1=O
-
Chemical Name1,3-dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]-2H-pyrrolo[3,2-b]pyridin-2-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wood ER, et al. Bioorg Med Chem Lett, 2004, 14(4), 953-957.
molnova catalog
related products
-
SKF38393 HCl
SKF38393 HCl is a selective dopamine D1/D5 receptor agonist.
-
Zeaxanthin
Lutein and Zeaxanthin in neural tissue may have biological effects that include antioxidation, anti-inflammation, and structural actions.
-
Eleutheroside E
Eleutheroside E has anti-inflammatory effects by inhibiting NF-κB activities.
